Iterative Health secured $77 million in a Series C round to scale its AI- and technology-enabled clinical trial site network across cardiology and obesity, and to expand globally. The company said it will deepen support for provider and sponsor partners to accelerate patient enrollment and reduce trial start timelines. Iterative Health’s backers included Intrepid Growth Partners, Google Ventures and EDBI, alongside existing investors Insight Partners and Obvious Ventures. The firm claims activation speed improvements and enrollment lift relative to industry averages, and said it operates a network of 100+ sites across North America, Europe, India and Australia. Recent customer signaling includes a Palisade Bio engagement to support enrollment for a Phase II ulcerative colitis study, highlighting demand from disease-focused biotechs looking to de-risk trial execution.